Levocetirizine Dihydrochloride 5 mg + Montelukast Sodium 10 mg + Ambroxol Hydrochloride 75 mg Film-Coated Tablet

Levocetirizine Dihydrochloride 5 mg + Montelukast Sodium 10 mg + Ambroxol Hydrochloride 75 mg Film-Coated Tablet is a film-coated tablet formulated with Levocetirizine Dihydrochloride 5 mg + Montelukast Sodium 10 mg + Ambroxol Hydrochloride 75 mg. The active ingredient profile is Levocetirizine Dihydrochloride; Montelukast Sodium; Ambroxol Hydrochloride, placing the product in the antihistamine + leukotriene receptor antagonist + mucolytic combination category. The formulation combines antihistamine and leukotriene-modifying therapy with Ambroxol, a mucolytic/expectorant component intended to support mucus clearance. The film coating provides a finished oral solid-dosage presentation and may support handling, stability and product acceptability. For website cataloguing, composition, strength, dosage form and release/coating characteristics should be displayed prominently and consistently. The description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and the prescriber’s judgement. Prescription status, precautions, interactions, adverse effects and dosing must be checked against the current approved product label before publication. Manufacturer, licence, storage, shelf-life, pack configuration and market-specific regulatory details should be added only from verified product documentation.